# Tecentriq SC (atezolizumab) has been launched in India for treating certain types of lung cancer.

*biotech · news · 2026-05-15 · Firstpost*

## Key points

- Tecentriq SC, a seven-minute subcutaneous cancer immunotherapy, has launched in India for specific lung cancers.
- This is the world's first subcutaneous immunotherapy for lung cancer, reducing administration time by 80 percent.
- Tecentriq SC uses Halozyme's technology to make skin tissue more porous for efficient drug absorption.
- Roche claims the new method can lower cancer care costs in India by up to 80 percent.

**Companies:** Roche, Halozyme Therapeutics
**Countries:** India, Germany, United Kingdom, United States

[Read the full story on Firstpost](https://www.firstpost.com/explainers/whats-the-injectable-7-minute-cancer-drug-launched-in-india-14011629.html)

---

Canonical: https://newsio.io/n/c15e73c3-d370-42de-be54-c330f7233af1/tecentriq-sc-atezolizumab-has-been-launched-in-india-for-treating-certain-types
Summarized by Newsio from Firstpost. https://newsio.io/how-it-works